Therapy-Related Myeloid Neoplasms

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• The 2008 World Health Organization classification groups acute myeloid leukemia (AML) and myelodysplastic syndrome post-therapy as therapy-related myeloid neoplasms (TR-MNs).
• The universal acceptance of TR-MNs is debated due to confounding variables in attributing these conditions to prior therapies.

Purpose of the Study:

• To discuss TR-MNs, comparing their differences and similarities with de novo myeloid neoplasms.
• To analyze how TR-MN diagnosis impacts patient outcomes.
• To explore the pathogenesis of TR-MNs and genetic susceptibility.

Main Methods:

• Review of cases from the 2013 Society for Hematopathology/European Association for Haematopathology Workshop.
• Discussion of myeloid neoplasms considered likely TR-MNs.
• Analysis of data on patient outcomes and genetic abnormalities in TR-MNs.

Main Results:

• TR-MN diagnosis affects patient outcomes only in specific subsets.
• Therapy-related AML with recurrent genetic abnormalities (e.g., t(15;17), inv(16), t(8;21)) showed similar clinical outcomes to de novo counterparts.
• Patients with TR-MNs may have higher genetic susceptibility, while most treated patients do not develop these conditions.

Conclusions:

• Studying TR-MNs offers insights into the pathogenesis of de novo myeloid diseases.
• Understanding TR-MN development may elucidate why certain individuals are susceptible.
• Further research will critically reappraise current concepts of TR-MNs.